share_log

Bristol-Myers Squibb | DEFA14A: Others

Bristol-Myers Squibb | DEFA14A: Others

施貴寶 | DEFA14A:其他
美股sec公告 ·  03/28 22:39
Moomoo AI 已提取核心訊息
Bristol-Myers Squibb, a leading pharmaceutical company, has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy statement. This filing, pursuant to Section 14(a) of the Securities Exchange Act of 1934, indicates that the materials are intended for further communication with the company's shareholders in relation to the proxy solicitation. The company has confirmed that no filing fee is required for this submission. The nature of the additional materials has not been specified in the announcement.
Bristol-Myers Squibb, a leading pharmaceutical company, has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy statement. This filing, pursuant to Section 14(a) of the Securities Exchange Act of 1934, indicates that the materials are intended for further communication with the company's shareholders in relation to the proxy solicitation. The company has confirmed that no filing fee is required for this submission. The nature of the additional materials has not been specified in the announcement.
領先的製藥公司百時美施貴寶已向美國證券交易委員會(SEC)提交了明確的補充材料,作爲其委託書的一部分。根據1934年《證券交易法》第14(a)條,該文件表明,這些材料旨在與公司股東就代理招標進行進一步溝通。該公司已確認本次提交不需要任何申請費。公告中未具體說明額外材料的性質。
領先的製藥公司百時美施貴寶已向美國證券交易委員會(SEC)提交了明確的補充材料,作爲其委託書的一部分。根據1934年《證券交易法》第14(a)條,該文件表明,這些材料旨在與公司股東就代理招標進行進一步溝通。該公司已確認本次提交不需要任何申請費。公告中未具體說明額外材料的性質。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息